Nonprofit

Psychedelic Access Fund


  • About Us

    The Psychedelic Access Fund (PAF) is a non-profit organization determined to remove the financial barriers that prevent a person from experiencing psychedelic healing.

    We believe that psychedelic healing should be accessible to all, regardless of their ability to pay for it. 

    With psychedelics showing to be a promising treatment for our nation’s mental health crisis, we now have an opportunity to deliver a new healing modality. Oregon has been the first state to legalize psilocybin-assisted therapy, which will cost between $1,500-$3,500 per session. The Multidisciplinary Association for Psychedelic Studies (MAPS) anticipates that MDMA-assisted therapy programs will cost between $13,000 -$15,000 per patient, and we are yet to understand the cost for psilocybin-assisted therapy. With depression and anxiety being three times more likely in lower socioeconomic classes, our nation will be left in an imbalance, where only those who can afford psychedelic healing will have access. The Psychedelic Access Fund aims to solve that problem. 

    PAF will sponsor select individuals for healing opportunities in hopes of creating a healed, conscious, and connected world. We will also partner with psychedelic facilities and retreat centers to establish “Pay It Forward” funds and scholarship programs, so that no person is turned away from psychedelic healing due to their inability to pay.

    The Psychedelic Access Fund (PAF) is a non-profit organization determined to remove the financial barriers that prevent a person from experiencing psychedelic healing.

    We believe that psychedelic healing should be accessible to all, regardless of their ability to pay for it. 

    With psychedelics showing to be a promising treatment for our nation’s mental health crisis, we now have an opportunity to deliver a new healing modality. Oregon has been the first state to legalize psilocybin-assisted therapy, which will cost between $1,500-$3,500 per session. The Multidisciplinary Association for Psychedelic Studies (MAPS) anticipates that MDMA-assisted therapy programs will cost between $13,000 -$15,000 per patient, and we are yet to understand the cost for psilocybin-assisted therapy. With depression and anxiety being three times more likely in lower socioeconomic classes, our nation will be left in an imbalance, where only those who can afford psychedelic…

    Issue Areas Include

    Location & Contact

    Illustration

    Discover Your Calling

    Find opportunities to change the world with the latest social-impact job, internship, and volunteer listings. Plus, explore resources for taking action in your community.